Does TACROLIMUS Cause Dyslipidaemia? 149 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 149 reports of Dyslipidaemia have been filed in association with TACROLIMUS (Tacrolimus). This represents 0.2% of all adverse event reports for TACROLIMUS.
149
Reports of Dyslipidaemia with TACROLIMUS
0.2%
of all TACROLIMUS reports
5
Deaths
45
Hospitalizations
How Dangerous Is Dyslipidaemia From TACROLIMUS?
Of the 149 reports, 5 (3.4%) resulted in death, 45 (30.2%) required hospitalization, and 15 (10.1%) were considered life-threatening.
Is Dyslipidaemia Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TACROLIMUS. However, 149 reports have been filed with the FAERS database.
What Other Side Effects Does TACROLIMUS Cause?
Off label use (8,718)
Drug ineffective (6,214)
Product use in unapproved indication (5,057)
Acute kidney injury (4,005)
Transplant rejection (3,526)
Cytomegalovirus infection (3,320)
Covid-19 (3,201)
Drug interaction (2,896)
Diarrhoea (2,854)
Toxicity to various agents (2,845)
What Other Drugs Cause Dyslipidaemia?
OLANZAPINE (230)
ROSUVASTATIN (206)
ARIPIPRAZOLE (185)
METHOTREXATE (175)
QUETIAPINE (161)
ATORVASTATIN (155)
RISPERIDONE (154)
METFORMIN (151)
ZIPRASIDONE (149)
PREDNISONE (148)
Which TACROLIMUS Alternatives Have Lower Dyslipidaemia Risk?
TACROLIMUS vs TACROLIMUS\TACROLIMUS ANHYDROUS
TACROLIMUS vs TADALAFIL
TACROLIMUS vs TAFAMIDIS
TACROLIMUS vs TAFAMIDIS MEGLUMINE
TACROLIMUS vs TAFASITAMAB